Sugi Predict

Sugi Predict / Targets / CXCR2

CXCR2

C-X-C chemokine receptor type 2 · P25025 · CXCR2 on Sugi Atlas →

56,081 patent compounds predicted against CXCR2, 28,490 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Navarixin Anhydrous Navarixin Anhydrous (SCHEMBL184744) 1.00 20/20
SCHEMBL247103 SCHEMBL247103 1.00 20/20
SCHEMBL247339 SCHEMBL247339 1.00 20/20
SCHEMBL248387 SCHEMBL248387 1.00 20/20
SCHEMBL248562 SCHEMBL248562 1.00 20/20
SCHEMBL248828 SCHEMBL248828 1.00 20/20
SCHEMBL345883 SCHEMBL345883 1.00 20/20
SCHEMBL345884 SCHEMBL345884 1.00 20/20
SCHEMBL248693 SCHEMBL248693 0.81 20/20
SCHEMBL246917 SCHEMBL246917 0.81 20/20
SCHEMBL212454 SCHEMBL212454 0.81 20/20
SCHEMBL246919 SCHEMBL246919 0.81 20/20
SCHEMBL213072 SCHEMBL213072 0.80 20/20
SCHEMBL334294 SCHEMBL334294 0.79 20/20
SCHEMBL334295 SCHEMBL334295 0.79 20/20
SCHEMBL334528 SCHEMBL334528 0.79 20/20
SCHEMBL334760 SCHEMBL334760 0.78 20/20
SCHEMBL334838 SCHEMBL334838 0.75 20/20
SCHEMBL334881 SCHEMBL334881 0.74 20/20
SCHEMBL334867 SCHEMBL334867 0.74 20/20

Clinical trials — most relevant to CXCR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia PHASE3COMPLETED
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar PHASE2/PHASE3UNKNOWN
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma PHASE1/PHASE2COMPLETED
First Time in Human Study With GSK1325756 PHASE1COMPLETED
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer PHASE1UNKNOWN
Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors PHASE1COMPLETED
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma PHASE1COMPLETED
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study EARLY_PHASE1RECRUITING
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib nanCOMPLETED
Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease nanCOMPLETED
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease nanCOMPLETED
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
Activation and Recruitment of GIL During Hp Infection nanUNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination. nanENROLLING_BY_INVITATION
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA nanRECRUITING
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN
This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women nanNOT_YET_RECRUITING
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
Effect of Non-surgical Treatment of Periodontitis Patients Focusing on Inflammatory Mediators in Gingival Crevicular Fluid nanCOMPLETED
Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients nanRECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing ThroughMarrow-Blood Barrier nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CXCR2 binder may also engage these)

ProteinNameSimilarity
Q28807 — 1.000 Q28807 →
P55919 — 1.000 P55919 →
P21109 — 1.000 P21109 →
O97571 — 1.000 O97571 →
Q2YEG0 — 1.000 Q2YEG0 →
Q28003 — 1.000 Q28003 →
P70612 — 1.000 P70612 →
P55920 — 1.000 P55920 →
Q28422 — 1.000 Q28422 →
CXCR1 C-X-C chemokine receptor type 1 0.999 landscape →
P35344 — 0.998 P35344 →
Q28519 — 0.998 Q28519 →
Q2YEG2 — 0.998 Q2YEG2 →
Q2YEF9 — 0.998 Q2YEF9 →
Q810W6 — 0.997 Q810W6 →
P56498 — 0.996 P56498 →
Q3LSL6 — 0.995 Q3LSL6 →
P35411 — 0.995 P35411 →
Q95NC6 — 0.995 Q95NC6 →
P35343 — 0.995 P35343 →
CCR7 C-C chemokine receptor type 7 0.995 landscape →
CCR1 C-C chemokine receptor type 1 0.995 landscape →
P35407 — 0.995 P35407 →
O97878 — 0.994 O97878 →
P25930 — 0.994 P25930 →
Q9BGN6 — 0.994 Q9BGN6 →
Q5MD62 — 0.994 Q5MD62 →
CXCR4 C-X-C chemokine receptor type 4 0.994 landscape →
Q95NC4 — 0.994 Q95NC4 →
Q95NC0 — 0.994 Q95NC0 →